Understanding BP -- most of the chemos are already generic and not a BP revenue stream.
Pfizer just committed a potential $1 billion for a new oncology partnership. And many other BP has have been very aggressive in oncology with their partnerships and acquisitions -- but nobody has touched an OTC penny stock pumper such as Cytodyn. And every one of them has all the time and money to buy CYDY and NOBODY has touched them. The mTNBC data reporting is a muddled mess and no REAL clinical trial data has actually been released. So bad, that the SEC is investigating it. What is the real data?? Dr. Kelly won't release the real data, just all the dubious unvalidated model data, muddled compassionate care R/R and naive Ph1 data. Even the FDA rejected it as not "breakthrough," But now NP is posing a lame story that more time for the trial was required and they need to call up all the patients. What kind of trial is that??
Sorry, it is going to take a substantial Phase 2 trial that will take several years. This current mess is not adequate for BTD or to convince a BP. Cytotyn has no credibility for clinical data (remember the FDA Statement) and this data is doing nothing to improve their reputation.